You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Details for Patent: 7,598,279


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 7,598,279 protect, and when does it expire?

Patent 7,598,279 protects XCOPRI and is included in one NDA.

This patent has twenty-four patent family members in twenty countries.

Summary for Patent: 7,598,279
Scope and claims summary:
Title:Neurotherapeutic azole compounds
Abstract: Azole compounds containing carbamoyl group and pharmaceutically useful salts thereof are described. The compounds are effective anticonvulsants which are used in the treatment of disorders of the central nervous system, especially as anxiety, depression, convulsion, epilepsy, migraine, bipolar disorder, drug abuse, smoking, ADHD, obesity, sleep disorder, neuropathic pain, stroke, cognitive impairment, neurodegeneration, stroke and muscle spasm.
Inventor(s): Choi; Yong Moon (Pinebrook, NJ), Kim; Choon-Gil (Daejon, KR), Yi; Han-Ju (Daejeon, KR), Kang; Young-Sun (Daejeon, KR), Lee; Hyun-Seok (Daejeon, KR)
Assignee: SK Holdings Co., Ltd. (Seoul, KR)
Application Number:11/407,526
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 7,598,279

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sk Life XCOPRI cenobamate TABLET;ORAL 212839-001 Mar 10, 2020 RX Yes Yes 7,598,279 ⤷  Subscribe Y ⤷  Subscribe
Sk Life XCOPRI cenobamate TABLET;ORAL 212839-002 Mar 10, 2020 RX Yes No 7,598,279 ⤷  Subscribe Y ⤷  Subscribe
Sk Life XCOPRI cenobamate TABLET;ORAL 212839-003 Mar 10, 2020 RX Yes No 7,598,279 ⤷  Subscribe Y ⤷  Subscribe
Sk Life XCOPRI cenobamate TABLET;ORAL 212839-004 Mar 10, 2020 RX Yes No 7,598,279 ⤷  Subscribe Y ⤷  Subscribe
Sk Life XCOPRI cenobamate TABLET;ORAL 212839-005 Mar 10, 2020 RX Yes No 7,598,279 ⤷  Subscribe Y ⤷  Subscribe
Sk Life XCOPRI cenobamate TABLET;ORAL 212839-006 Mar 10, 2020 RX Yes No 7,598,279 ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,598,279

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1879873 ⤷  Subscribe 301106 Netherlands ⤷  Subscribe
European Patent Office 1879873 ⤷  Subscribe 122021000027 Germany ⤷  Subscribe
European Patent Office 1879873 ⤷  Subscribe CA 2021 00015 Denmark ⤷  Subscribe
European Patent Office 1879873 ⤷  Subscribe 2021C/524 Belgium ⤷  Subscribe
European Patent Office 1879873 ⤷  Subscribe 19/2021 Austria ⤷  Subscribe
European Patent Office 1879873 ⤷  Subscribe C202130027 Spain ⤷  Subscribe
European Patent Office 1879873 ⤷  Subscribe 132021000000101 Italy ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.